Even as the controversy over Baba Ramdev's infertility medicine rages on, union Food, Public Distribution and Consumer Protection Minister Ram Vilas Paswan said on Friday that its advertisement cannot be classified as "misleading" and assured that the matter was being probed.
"When people don't get the promised results as claimed by a product, then only it can be termed as misleading... This product cannot be classified under misleading advertisement," he told media persons here.
"The issue which is raging on in parliament is about when the government is promoting 'Beti Bachao, Beti Padhao' campaign, why is this medicine promoting only male child," he said.
According to Paswan, while allopathic medicines can be tested in laboratories and thereafter animal-testing can be done to analyse its "effects and after-effects", homeopathic and ayurvedic medicines cannot be done so.
"Promoting only a male child is illegal... The union home and heath ministers are already looking into it," he said.
The issue had caused an uproar in the Rajya Sabha on Thursday when members raising the issue of the product, 'Divya Putrajeevak Seed' and seeking a response from the government. Health Minister J.P. Nadda assured that the government "will look into it and action will be taken".
The website of Ramdev's Divya Pharmacy prices the product at $10.99 and the description says it is a "unique herbal product of putrajeevak which is aphrodisiac, controls habitual abortion and helps in (curing) sterility".
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
